期刊
SCIENCE
卷 349, 期 6246, 页码 436-440出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaa1663
关键词
-
资金
- American Society of Hematology Bridge award
- Cincinnati Children's Hospital Medical Center Gap Award
- Divisional Funds from Immunobiology and Bone Marrow Transplantation and Immune Deficiency
- Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), NIH
- Merck, Inc.
- NIH [1RC2 HG005608]
- Division of Intramural Research, NIAID, NIH [1ZIAAI000769-14]
Mutations in the LRBA gene (encoding the lipopolysaccharide-responsive and beige-like anchor protein) cause a syndrome of autoimmunity, lymphoproliferation, and humoral immune deficiency. The biological role of LRBA in immunologic disease is unknown. We found that patients with LRBA deficiency manifested a dramatic and sustained improvement in response to abatacept, a CTLA4 (cytotoxic T lymphocyte antigen-4)-immunoglobulin fusion drug. Clinical responses and homology of LRBA to proteins controlling intracellular trafficking led us to hypothesize that it regulates CTLA4, a potent inhibitory immune receptor. We found that LRBA colocalized with CTLA4 in endosomal vesicles and that LRBA deficiency or knockdown increased CTLA4 turnover, which resulted in reduced levels of CTLA4 protein in FoxP3(+) regulatory and activated conventional Tcells. In LRBA-deficient cells, inhibition of lysosome degradation with chloroquine prevented CTLA4 loss. These findings elucidate a mechanism for CTLA4 trafficking and control of immune responses and suggest therapies for diseases involving the CTLA4 pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据